AstraZeneca (AZN.L) is working as fast as possible to compile data on its COVID-19 vaccine to apply for U.S. approval but the dataset is very big, executives said on Friday as the drugmaker faces delays to its submission.
A vial and sryinge are seen in front of a displayed AstraZeneca logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustrationis working as fast as possible to compile data on its COVID-19 vaccine to apply for U.S. approval but the dataset is very big, executives said on Friday as the drugmaker faces delays to its submission.
"There's a lot more data than just a Phase III study and so we're working as fast as we can to pull it all together and submit," said Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca. Chief executive Pascal Soriot said in a briefing following the release of first-quarter results there was nothing wrong with the data, but the dataset was very big.
On Friday, the company said it planned to apply for U.S. approval in the coming weeks. That is a delay from late March when the company also said it would submit the data in the coming weeks.Our Standards:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Covid:19: Nisra records slight increase in NI Covid deathsCovid-19 was mentioned on the death certificates of eight people in NI up to Friday 30 April.
Read more »
Covid-19: Some Covid safeguards needed after June, says RaabBut the foreign secretary says the UK is in a 'good position' for life to be 'close to normal' again.
Read more »
WSJ News Exclusive | AstraZeneca Struggles With Data Needed for Covid-19 Vaccine’s ApprovalThe drugmaker is grappling with delays in its efforts to seek U.S. authorization for its shot, with FDA signoff seen as critical to vaccine drives around the world.
Read more »
AstraZeneca Q1 COVID-19 vaccine revenue $275 mlnAstraZeneca (AZN.L) said on Friday its COVID-19 vaccine contributed $275 million in sales and shaved off three cents per share from its first-quarter earnings, as the drugmaker reported better-than-expected results and forecast sales growth.
Read more »
Argentina pushes AstraZeneca on COVID-19 vaccine supply amid holdupsArgentina's government said on Wednesday that it met with representatives of drugmaker AstraZeneca Plc (AZN.L) to ask about 'difficulties' in the production of its COVID-19 vaccine and supply of it to the country.
Read more »